| 摘要 |
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:;
which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
;The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with compounds of Formula (I). |
| 主权项 |
1. A compound represented by Formula (I):or a pharmaceutically acceptable salt thereof, wherein:the moiety ofis represented by: Ring A is optionally substituted phenyl; Ring B is absent; L is C2-C4 alkynyl; G is selected from: J is wherein the 6-membered ring of J is attached to L, and, when G is a 5/6-fused membered heteroaryl, the 6-membered ring is attached to Ring A; R1 is hydrogen or optionally substituted C1-C4 alkyl; R6 at each occurrence is independently selected from the group consisting of optionally substituted O(C1-C8 alkyl); optionally substituted amino; C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, heterocyclic, aryl, and heteroaryl, each optionally substituted; Q is selected from: R3 and R4 are each independently selected from the group consisting of hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, and optionally substituted C3-C8 cycloalkyl; alternatively, R3 and R4 are taken together with the carbon atom to which they are attached to form optionally substituted C3-C8 cycloalkyl or optionally substituted heterocyclic; R5 is hydrogen, optionally substituted C1-C8 alkyl, or optionally substituted C3-C8 cycloalkyl; U is absent or selected from O, S, S(O), SO2, NC(O)—(C1-C4 alkyl), C(O), protected carbonyl, OCH2, OCH2CH2, SCH2, SCH2CH2, C(R7)2, and C(R7)2C(R7)2; R7 at each occurrence is independently selected from the group consisting of hydrogen, halogen, cyano, hydroxy, O(C1-C4 alkyl), S(C1-C4 alkyl), amino optionally substituted with one or two C1-C4 alkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted C1-C4 alkyl; alternatively two geminal R7 groups are taken together with the carbon atom to which they are attached to form a spiro, optionally substituted 3- to 8-membered ring selected from the group consisting of C3-C8 cycloalkyl, C3-C8 cycloalkenyl and 3- to 8-membered heterocyclic; and R7a and R7b are each independently selected from the group consisting of hydrogen, optionally substituted aryl, and optionally substituted C1-C4 alkyl; or alternatively, CHR7a-U or CHR7b-U are taken together to form a group selected from CH═CH, optionally substituted C3-C8 cycloalkyl, optionally substituted aryl, or optionally substituted heterocyclic; or alternatively, U, R7a, and R7b are taken together with the carbon atoms to which they are attached to form a bridged, optionally substituted 4- to 7-membered ring selected from the group consisting of C4-C7 cycloalkyl, C4-C7 cycloalkenyl and 4- to 7-membered heterocyclic, optionally substituted. |
